EN DE
Watch bioAffinity Technologies, Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

bioAffinity Technologies, Inc (BIAF) fair value: what the stock is really worth

As of Oct 21, 2026: fair value (intrinsic value) of bioAffinity Technologies, Inc stock $3.03, price $3.57, upside -15.1%, quality 40 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US

BT bioAffinity Technologies, Inc logo Thin data Oct 21, 2026

bioAffinity Technologies, Inc

BIAF · US

Weak valuationQuality is weak on top of the rich price.

Our calculation puts a fair price 15% below what the stock costs today.

Low debt
Ranks above peers (5/7)
Quality 40/100
Mixed Growth (revenue 3y +986.6 %/yr in USD)
Fair value $3.03 · Overvalued (−15.1%)
Negative free cash flow
Narrow moat 19/100 · thin data
Thin data
Watch bioAffinity Technologies, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$3,735 $3.51 Fair Value $3.03 Sep 2022 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 21, 2026.

How to read this chart

50‑month range $3.51 – $3,735 · fair‑value band $2.00 – $3.78 · the $3.57 price screens above the $3.03 fair value. Dashed = 300-day average. As of Oct 21, 2026.

Follow bioAffinity Technologies in your weekly email

Every Wednesday you see whether bioAffinity Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States.

Show moreShow less

The company operates through two segments: Diagnostic Research and Development; and Laboratory Services.

The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.

The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

Stock analysis

bioAffinity Technologies, Inc (BIAF) currently trades at $3.57, while our model-based Fair Value estimate is $3.03, 15.1% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $2.00 (bear) to $3.78 (bull), the price of $3.57 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

bioAffinity Technologies, Inc reported revenue of $6.2M in FY2025 versus $1.3K in FY2021, a compound +728.8%/yr. Reported net income was −$14.9M in FY2025.

Key figures

Market cap $4.5M Micro · P/S ratio 0.77 · EPS (TTM) $−109.35 · Return on equity −1,860% · Return on assets (EBIT) −103% · Operating margin −221% · Revenue (TTM) $5.9M · Revenue growth (YoY) +19.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 19 out of 100 (low confidence).

What moves the price

The share trades about 95% below its 52-week high and 2% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −15%, BIAF screens richer than that median.

Fair Value models

Bear $2.00 Fair Value $3.03 Bull $3.78
Price $3.57 · Upside -15.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $2.00 $3.03 $3.78 55
All 1 models by family
Asset-Based
NCAV (Graham) $2.00 $3.03 $3.78 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 12
How much profit the company makes from its sales and capital
Quality Growth 16
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Momentum 0
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 59
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−34.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+986.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−168,975.7% (2021) → −171.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

BIAF screens overvalued: fair value 15% below the price. Compare with Thermo Fisher Scientific Inc →

Compare bioAffinity Technologies, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 124 stocks

Beats the industry median on 5/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 40 · Bottom 25%
Fair Value upside −17.2% · Above median
Profitability
Return on assets −136.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 19.0% · Top 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.63× · Cheapest 25%
P/S (12 months) 0.77× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)13 · sector 0
FUTURE (revenue growth)95 · sector 28
PAST (return on equity)0 · sector 13
HEALTH (low debt)100 · sector 95
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥147.35 ¥164.66 +12% vs BIAF
IQVIA Holdings IQV $276.63 $299.94 +8% vs BIAF
Illumina, Inc ILMN $282.86 $297.04 +5% vs BIAF
Thermo Fisher Scientific Inc TMO $679.38 $686.04 +1% vs BIAF
Danaher Corporation DHR $224.24 $209.18 −7% vs BIAF
IDEXX Laboratories, Inc IDXX $553.48 $496.48 −10% vs BIAF
Mettler-Toledo International Inc MTD $1,678 $648.30 −61% vs BIAF
Agilent Technologies, Inc A $177.75 $64.53 −64% vs BIAF
Lonza Group LONN CHF 623.60 CHF 153.50 −75% vs BIAF
Waters Corporation WAT $457.47 $107.35 −77% vs BIAF

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

bioAffinity Technologies, Inc · Fair Value
$3.03 −15%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "bioAffinity Technologies, Inc Fair Value". https://www.fairvalue-calculator.com/stock/BIAF

Frequently asked questions

Is bioAffinity Technologies, Inc (BIAF) overvalued or undervalued?
As of Oct 21, 2026, our model estimates a fair value of $3.03 versus a price of $3.57, about −15% upside (overvalued).
What is the fair value of BIAF?
Our model-based fair value for bioAffinity Technologies, Inc is $3.03 (as of Oct 21, 2026), built from audited fundamentals. The current price: $3.57.
What is the quality score of BIAF?
bioAffinity Technologies, Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for bioAffinity Technologies, Inc (BIAF)?
Our model-based price target is the fair value of $3.03 (as of Oct 21, 2026) from 1 valuation models. Cautious scenario $2.00, optimistic scenario $3.78. It is a calculation from audited fundamentals, not an analyst target.
What is the bioAffinity Technologies, Inc stock forecast for 2026?
Our models put fair value at $3.03, about −15% upside versus a price of $3.57 (overvalued). Cautious scenario $2.00, optimistic scenario $3.78. The calculation is refreshed regularly with new filings.
What is the revenue of bioAffinity Technologies, Inc (BIAF)?
bioAffinity Technologies, Inc reported trailing-twelve-month revenue of about $5.9M (latest available figure, as of Oct 21, 2026).
What is the intrinsic value of bioAffinity Technologies, Inc (BIAF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For bioAffinity Technologies, Inc it is $3.03 per share (as of Oct 21, 2026), against a price of $3.57. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is bioAffinity Technologies, Inc stock overvalued or undervalued in 2026?
As of Oct 21, 2026, BIAF trades above its calculated fair value: price $3.57, fair value $3.03, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIAF?
No. The price is what the market pays today ($3.57); the fair value is what the company's own numbers justify ($3.03). For bioAffinity Technologies, Inc the two are $0.5400 per share apart. That gap is exactly why we show both numbers side by side.
How much is bioAffinity Technologies, Inc worth?
The market values bioAffinity Technologies, Inc at about $4.5M (market capitalisation, as of Oct 21, 2026). Per share that is $3.57; our models calculate a fair value of $3.03 per share.
What do the bullish and bearish scenarios say about BIAF?
Our models span a range for bioAffinity Technologies, Inc: cautious scenario $2.00, base $3.03, optimistic $3.78 per share (as of Oct 21, 2026, price $3.57). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of bioAffinity Technologies, Inc (BIAF)?
Balance-sheet figures for bioAffinity Technologies, Inc (as of Oct 21, 2026): debt of 0.01 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is BIAF from its 52-week high?
bioAffinity Technologies, Inc trades at $3.57, about 95% below its 52-week high of $71.10 and 2% above the low of $3.51 (as of Oct 21, 2026). Distance from the high says nothing about value: that is what the fair value of $3.03 is for.
Which stocks are comparable to bioAffinity Technologies, Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is bioAffinity Technologies, Inc stock attractive at the current price?
The data as of Oct 21, 2026: price $3.57, calculated fair value $3.03 (−15%), Quality Score 40/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BIAF calculated?
We run bioAffinity Technologies, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.03, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6 % above its aggregate fair value. bioAffinity Technologies, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of bioAffinity Technologies, Inc (BIAF)?
The closing price on Oct 21, 2026 was $3.57. Our model-based fair value is $3.03, about −15% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with bioAffinity Technologies, Inc right now?
Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range ($2.00 to $3.78) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of bioAffinity Technologies, Inc

How large is the market capitalisation of bioAffinity Technologies, Inc (BIAF)?
The market capitalisation of bioAffinity Technologies, Inc is $4.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of bioAffinity Technologies, Inc (BIAF)?
The price-to-sales ratio of bioAffinity Technologies, Inc is 0.77 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of bioAffinity Technologies, Inc (BIAF)?
Earnings per share at bioAffinity Technologies, Inc are $−109.35. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of bioAffinity Technologies, Inc (BIAF)?
The return on equity (ROE) of bioAffinity Technologies, Inc is −1,860% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of bioAffinity Technologies, Inc (BIAF)?
On an EBIT basis the return on assets of bioAffinity Technologies, Inc is −103% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of bioAffinity Technologies, Inc (BIAF)?
The operating margin of bioAffinity Technologies, Inc is −221% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at bioAffinity Technologies, Inc (BIAF)?
Revenue at bioAffinity Technologies, Inc is growing +19.0% versus a year earlier (3y avg +987%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does bioAffinity Technologies, Inc (BIAF) generate?
The free cash flow of bioAffinity Technologies, Inc is −$9.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does bioAffinity Technologies, Inc (BIAF) hold?
bioAffinity Technologies, Inc holds more cash than debt, $5.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch bioAffinity Technologies, Inc in the live analysis

One click puts bioAffinity Technologies, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.